It took 16 years of twists and turns. Over and over, Dr. Nancy Sullivan thought she was close to an Ebola vaccine, only to see the next experiment fail. But it is those failures that Sullivan credits for finally leading her to a vaccine promising enough to test in parts of West Africa ravaged by Ebola.
About 10 percent of young leukemia patients of East Asian ancestry inherit a gene variation that...
The measles outbreak with roots in Disneyland continues to spread, with at least 75 confirmed...
The first study will compare the two experimental vaccines with dummy shots in hopes of proving...
Warren's bill would require that whenever drug companies enter into a settlement with the government over alleged wrongdoing, they must pay a portion of their annual profits over five years to support research at the NIH and the FDA.
AMRI has received a 10-year federal contract award from the NIH for drug development and manufacturing services. This NIH/National Institute of Neurological Disorders and Stroke award will support NIH's Drug Manufacturing and Formulation Program, which is a component of the Blueprint Neurotherapeutics Network. AMRI has supported the NIH BPN since 2011, providing chemistry services and discovery technologies.
More than 100 million Americans suffer from chronic pain, with five to eight million needing powerful narcotics to fight the pain. However, an expert panel is declaring there is little evidence these treatment programs work
The National Institutes of Health says the U.S. alone consumes three-quarters of the world’s prescriptions drugs despite accounting for just 5 percent of its population, and when symptoms subside, treatment directives change or medications expire, options for disposing of the remaining doses can be limited.
There's no skunky bar odor amid the beer taps. Instead of booze, colored water fills the bottles. The real alcohol is locked away but still close enough for the extra temptation of smell — and to test the safety of a new drug designed to help heavy drinkers say "when" sooner than usual.
Even as tobacco smoking by teens dropped to new lows, use of e-cigarettes reached levels that surprised researchers. The findings marked the survey's first attempt to measure the use of e-cigarettes by people that young.
Declaring the "fight is nowhere close to being over," President Barack Obama heralded strides in the effort to confront Ebola in West Africa and in protecting the U.S. against the spread of the deadly virus. He said squelching the disease remains an urgent priority even if the American public's attention has shifted elsewhere.
An experimental Ebola vaccine appears safe and triggered signs of immune protection in the first 20 volunteers to test it, U.S. researchers have reported. The vaccine is designed to spur the immune system's production of anti-Ebola antibodies.
Doctors and patients may soon find it easier to learn if clinical trials of treatments worked or not, as the government proposed new rules Wednesday expanding what researchers are required to publicly report.
Health officials are scrambling to begin human testing of a handful of experimental drugs for Ebola. But the effort has sparked an ethical debate over how to study unproven medicines amid an outbreak that has killed nearly 5,000.
For Americans wondering why President Barack Obama hasn't forced all states to follow a single, national rule for isolating potential Ebola patients, the White House has a quick retort: Talk to the Founding Fathers.
The Swiss agency that regulates new drugs has approved an application for a clinical trial with an experimental Ebola vaccine at the Lausanne University Hospital. Swissmedic said the trial will be conducted among 120 volunteer participants with support from the U.N. World Health Organization.
The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March. Still, the agency warned it's not clear whether any of these will work against the deadly virus that has...
Both Dallas nurses infected while treating an Ebola patient have been flown to better equipped facilities.
Ebola has arrived in the United States and people are frightened. The nation's top infectious diseases expert says it's perfectly normal to feel anxious about a virus that kills so fast and is ravaging parts of West Africa.
As West Africa's Ebola outbreak continues to rage, some experts are coming to the conclusion that it may take large amounts of vaccines and maybe even drugs — all still experimental and in short supply — to bring the outbreak under control.
An American doctor who was exposed to the Ebola virus while volunteering in Sierra Leone was admitted Sunday to a hospital at the National Institutes of Health near the nation's capital.
Navidea Biopharmaceuticals today announced the receipt of an initial notice of award for a Fast Track Small Business Innovation Research (SBIR) grant providing for up to $1.67 million from the National Cancer Institute (NCI), National Institutes of Health (NIH), to fund evaluation of Lymphoseek ® (technetium Tc 99m tilmanocept) Injection in women with cervical cancer.
The objectives of the contract are to advance the development of Soligenix's thermostabilization technology, ThermoVax, combined with the company's ricin toxin vaccine, Rivax, as a medical countermeasure (MCM) to prevent the effects of ricin exposure.
It's incredibly unlikely that Ebola would mutate to spread through the air, and the best way to make sure it doesn't is to stop the epidemic, a top government scientist told concerned lawmakers Wednesday.
British scientists say a former nurse has become the first person in the country to receive an experimental Ebola vaccine in an early trial to test its safety. Ruth Atkins, 48, got the injection on Wednesday in Oxford, the first of 60 healthy volunteers in the U.K. who will receive the vaccine.
PharmAthene Awarded Contract Of Up To $28.1M to Develop Next Generation Thermostable Anthrax VaccineSeptember 10, 2014 9:12 am | News | Comments
PharmAthene announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded the company a contract, valued at up to $28.1M if all contract options are exercised, for the development of a next generation anthrax vaccine based on the company's proprietary rPA anthrax vaccine technology platform.
The National Institutes of Health said it has uncovered a nearly century-old container of ricin and a handful of other forgotten samples of dangerous pathogens as it combs its laboratories for improperly stored hazardous materials.
New monkey studies show that one shot of an experimental Ebola vaccine can trigger fast protection, but the effect waned unless the animals got a booster shot made a different way.
The National Institutes of Health announced Thursday that it is launching the safety trial on a vaccine developed by the agency's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline. It will test 20 healthy adult volunteers to see if the virus is safe and triggers an adequate response in their immune systems.
- Page 1